These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 11278284

  • 1. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis.
    Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS.
    J Biol Chem; 2001 Apr 06; 276(14):10767-74. PubMed ID: 11278284
    [Abstract] [Full Text] [Related]

  • 2. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.
    Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK.
    Oncogene; 2001 Sep 20; 20(42):6073-83. PubMed ID: 11593415
    [Abstract] [Full Text] [Related]

  • 3. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP.
    Rokhlin OW, Guseva NV, Tagiyev AF, Glover RA, Cohen MB.
    Prostate; 2002 Jun 01; 52(1):1-11. PubMed ID: 11992615
    [Abstract] [Full Text] [Related]

  • 4. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
    Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK.
    J Biol Chem; 2001 Oct 19; 276(42):38361-9. PubMed ID: 11461904
    [Abstract] [Full Text] [Related]

  • 5. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
    Kandasamy K, Srivastava RK.
    Cancer Res; 2002 Sep 01; 62(17):4929-37. PubMed ID: 12208743
    [Abstract] [Full Text] [Related]

  • 6. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X, Li H.
    Cancer Lett; 2004 Jul 08; 210(1):63-71. PubMed ID: 15172122
    [Abstract] [Full Text] [Related]

  • 7. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells.
    Beresford SA, Davies MA, Gallick GE, Donato NJ.
    J Interferon Cytokine Res; 2001 May 08; 21(5):313-22. PubMed ID: 11429162
    [Abstract] [Full Text] [Related]

  • 8. TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP.
    Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Syrbu SI, Cohen MB.
    Cancer Biol Ther; 2002 May 08; 1(6):631-7. PubMed ID: 12642685
    [Abstract] [Full Text] [Related]

  • 9. Wortmannin elevates tumor necrosis factor-related apoptosis-inducing ligand sensitivity in LNCaP cells through down-regulation of IAP-2 protein.
    Seol JW, Lee YJ, Kang HS, Kim IS, Kim NS, Kwak YG, Kim TH, Seol DW, Park SY.
    Exp Oncol; 2005 Jun 08; 27(2):120-4. PubMed ID: 15995629
    [Abstract] [Full Text] [Related]

  • 10. Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL).
    Eid MA, Lewis RW, Kumar MV.
    Mol Cancer Ther; 2002 Aug 08; 1(10):831-40. PubMed ID: 12492116
    [Abstract] [Full Text] [Related]

  • 11. Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells.
    Kulik G, Carson JP, Vomastek T, Overman K, Gooch BD, Srinivasula S, Alnemri E, Nunez G, Weber MJ.
    Cancer Res; 2001 Mar 15; 61(6):2713-9. PubMed ID: 11289152
    [Abstract] [Full Text] [Related]

  • 12. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells.
    Oka N, Nakahara S, Takenaka Y, Fukumori T, Hogan V, Kanayama HO, Yanagawa T, Raz A.
    Cancer Res; 2005 Sep 01; 65(17):7546-53. PubMed ID: 16140916
    [Abstract] [Full Text] [Related]

  • 13. hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways.
    Li H, Wang X, Li N, Qiu J, Zhang Y, Cao X.
    J Biol Chem; 2007 Feb 16; 282(7):4943-4950. PubMed ID: 17178731
    [Abstract] [Full Text] [Related]

  • 14. Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells.
    Wang Q, Wang X, Hernandez A, Hellmich MR, Gatalica Z, Evers BM.
    J Biol Chem; 2002 Sep 27; 277(39):36602-10. PubMed ID: 12140294
    [Abstract] [Full Text] [Related]

  • 15. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

  • 16. Overexpression of BAD potentiates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand treatment in the prostatic carcinoma cell line LNCaP.
    Taghiyev AF, Guseva NV, Harada H, Knudson CM, Rokhlin OW, Cohen MB.
    Mol Cancer Res; 2003 May 01; 1(7):500-7. PubMed ID: 12754297
    [Abstract] [Full Text] [Related]

  • 17. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells.
    Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA, Gautam SC.
    Mol Cancer Ther; 2003 Jan 01; 2(1):95-103. PubMed ID: 12533677
    [Abstract] [Full Text] [Related]

  • 18. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S, Almasan A.
    Cancer Res; 2003 Aug 01; 63(15):4713-23. PubMed ID: 12907654
    [Abstract] [Full Text] [Related]

  • 19. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

  • 20. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway.
    Deeb D, Jiang H, Gao X, Al-Holou S, Danyluk AL, Dulchavsky SA, Gautam SC.
    J Pharmacol Exp Ther; 2007 May 15; 321(2):616-25. PubMed ID: 17289836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.